Letter: programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort—more questions than answers. Authors’ reply

M. Pinter,B. Scheiner

DOI: https://doi.org/10.1111/apt.15334

2019-07-01

Abstract:EDITORS, We thank Drs Kung and Wang for their great interest in our paper and for acknowledging the new important evidence our study1 adds to the growing field of immunotherapy in hepatocellular carcinoma (HCC). We are also happy to respond to the questions and points of discussion that they raised.2 First, we did not observe reactivation of hepatitis B in our co‐ hort. Only one of the three patients who experienced hepatitis and required treatment with corticosteroids had chronic hepatitis B in‐ fection as underlying aetiology. That patient was put on anti‐viral treatment years before study inclusion and remained on anti‐viral therapy during the course of immunotherapy. Second, we agree that immunosuppression with steroids may in‐ crease the risk of infections. However, it remains unclear if patients on immunosuppression for treatment of immune‐related adverse events should receive concomitant prophylactic antibiotics to re‐ duce the risk of opportunistic infections.3 Notably, the use of antibiotics may negatively affect the efficacy of immune checkpoint inhibitors,4‐6 probably by modulating the gut microbiota.5 In our cohort, seven (11%) patients experienced different types of infections, but only one received prior systemic immunosup‐ pressive therapy to treat an adverse event. He was diagnosed with Candida oesophagitis around 3 months after steroid treatment. A causal relationship to immunosuppression may be possible. However, the fact that most patients included in our study had underlying cir‐ rhosis (half with Child‐Pugh stage B or C) could be an alternative ex‐ planation for the rate of infections that we observed. As both humoral and cell‐mediated immunity are impaired in patients with cirrhosis, infections are a common complication, particularly in those with de‐ compensated disease, and are associated with increased mortality.7 Finally, as radiation is not a standard therapy for HCC according to European guidelines,8 only two patients received prior radiation therapy in our cohort, which prevented further subgroup analyses. However, we agree that the combination of immunotherapy with treatment modalities that affect antigen release or modulate the tu‐ mour microenvironment (e.g., ablation, or anti‐angiogenic therapies) may potentially increase the efficacy of immunotherapy. Preliminary data from studies investigating such combinations have been prom‐ ising but need to be confirmed in larger trials.9 ACKNOWLEDG EMENT

Medicine